Ischemix names Robert DuFresne CEO
This article was originally published in Scrip
Executive Summary
Ischemix, a US biotechnology company developing compounds to reduce and/or prevent cell and organ damage associated with ischaemia-reperfusion injury caused by cardiac surgery, heart attack and stenting procedures, has named Robert DuFresne chief executive officer. The company's former CEO, Dr Reinier Beeuwkes, will continue to serve as president and chairman. Mr DuFresne has more than 25 years' experience in the biopharmaceutical industry, having most recently worked as president and CEO of Pacgen Biopharmaceuticals. He has served on Ischemix's board of directors since May 2007, a role in which he will continue.